<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Trading after the bell was relatively muted on Thursday, with small-cap biotech names showing modest shifts. Delcath Systems edged higher following its buyback announcement, while BioVie, Cassava Sciences, and Enlivex Therapeutics rebounded despite a lack of fresh headlines.</p><p><b>Delcath Systems, Inc. (DCTH)</b> rose in after-hours trading to $8.52, up 4.02% or $0.33. Earlier in the day, the stock had closed at $8.19, down 3.76% or $0.32. The rebound followed the company's announcement of a $25 million share repurchase program, which carries no expiration date and reflects confidence in its long-term outlook.</p><p><b>BioVie Inc. (BIVI)</b> climbed to $1.44 in extended trading, a gain of 13.39% or $0.17. This came after the stock ended the regular session at $1.27, down 7.30% or $0.10. The after-hours rally occurred despite no company-specific news on Thursday, suggesting speculative or technical-driven activity.</p><p><b>Cassava Sciences, Inc. (SAVA)</b> advanced to $2.87 after the bell, up 9.17% or $0.24. During the regular session, shares had slipped to $2.63, down 4.36% or $0.12. While no new headlines crossed Thursday, investors continue to digest the company's Q3 results reported November 12, which showed a narrower net loss of $10.8 million compared to $27.9 million a year earlier. Cassava ended the quarter with $106.1 million in cash and no debt, down from $128.6 million at year-end 2024.</p><p><b>Enlivex Therapeutics Ltd. (ENLV)</b> edged higher in after-hours trading to $0.95, up 4.24% or $0.04. Earlier, the stock had closed at $0.91, down 2.79% or $0.03. No company-specific news was released Thursday. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

DCTH

SAVA

ENLV

BIVI

<p>After-hours trading saw biotech stocks like Delcath Systems rise due to a $25 million buyback announcement, reflecting confidence in its long-term outlook. BioVie, Cassava Sciences, and Enlivex Therapeutics also rebounded despite no new headlines. Cassava's rise follows its Q3 results showing a reduced net loss and strong cash position.</p>

rttnews

Delcath

Cassava Sciences

Enlivex Therapeutics

Biovie

Biotech Stocks Swing After Hours: Delcath Rises On Buyback, BioVie And Cassava Rebound